IMPLANTABLE MEDICAL DEVICE

• US 20130225947A1
• Filed: 10/29/2010
• Published: 08/29/2013
• Est. Priority Date: 10/29/2010
• Status: Abandoned Application

• Current Assignee: St. Jude Medical AB (Abbott Laboratories Incorporated)
• Original Assignee: St. Jude Medical AB (Abbott Laboratories Incorporated)
• Inventors: Blomqvist, Andreas
• Application Number:
  US13/881,980
• Publication Number:
  US 20130225947A1
• Time in Patent Office: Days
• US Class Current: 600/301
• CPC Class Codes: A61B 5/0205 Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• CPC Class Codes: A61B 5/02416 using photoplethysmograph signals, e.g. generated by infrared radiation A61B5/14552 takes precedence
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/0261 using optical means, e.g. infrared light
• CPC Class Codes: A61B 5/0265 using electromagnetic means, e.g. electromagnetic flowmeter
• CPC Class Codes: A61B 5/0295 using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/14503 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence
• CPC Class Codes: A61B 5/14542 for measuring blood gases A61B5/14551 takes precedence
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/4869 Determining body composition
• CPC Class Codes: A61B 5/6846 specially adapted to be brought in contact with an internal body part, i.e. invasive
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 5/7282 Event detection, e.g. detecting unique waveforms indicative of a medical condition A61B5/4094, A61B5/4818, A61B5/349, A61B5/0823 take precedence
• CPC Class Codes: A61N 1/362 Heart stimulators heart defibrillators A61N1/39

Abstract

An implantable medical device comprising a coronary perfusion measurement unit is adapted to measure and determine parameters related to coronary perfusion of heart tissue. The parameters include time periods and perfusion magnitudes. The coronary perfusion measurement unit is configured to determine a time period T related to a perfusion event of a coronary vessel and including includes a reperfusion time period, where a perfusion event is defined as a decrease of coronary perfusion followed by reperfusion, and to generate a time period signal in dependence thereto. The implantable medical device further comprises a coronary flow calculation unit that is adapted to receive the time period signal and that is adapted to process the time period and to generate an ischemia risk indicating index I in dependence of the time period.

Claims

1. An implantable medical device comprising:

a coronary perfusion measurement unit adapted to measure and determine parameters related to coronary perfusion of heart tissue, the parameters including time periods and perfusion magnitudes, wherein the coronary perfusion measurement unit is configured to determine a time period T related to a perfusion event of a coronary vessel and includes a reperfusion time period, wherein the perfusion event is defined as a decrease of coronary perfusion followed by reperfusion, and wherein the coronary perfusion measurement unit is configured to generate a time period signal in dependence thereto; and

a coronary flow calculation unit adapted to receive the time period signal and adapted to process the time period and generate an ischemia risk indicating index I in dependence of the time period.

2. The implantable medical device according to claim 1, wherein the time period T is determined as the time period that starts when the perfusion magnitude is at its minimum and ends when the perfusion magnitude is back to an initial perfusion level.

3. The implantable medical device according to claim 1, wherein the ischemia risk indicating index I is directly dependent upon the time period T.

4. The implantable medical device according to claim 1, wherein the coronary perfusion measurement unit is adapted to determine a perfusion magnitude measure Δ

p during a perfusion event and to generate a magnitude signal that is applied to the coronary flow calculation unit, wherein the perfusion magnitude measure Δ

p is the magnitude difference between an initial perfusion level and the minimum perfusion level.

5. The implantable medical device according to claim 4, wherein a normalized ischemia risk indicating index I_norm is determined as I_norm=T/Δ

p.

6. The implantable medical device according to claim 1, wherein the implantable medical device further comprises an event detection unit, the event detection unit is arranged to detect an initiating event resulting in a perfusion event and is arranged to start a measurement window and activate the coronary perfusion measurement unit, upon detection of an initiating event, in order to determine the parameters related to the perfusion event.

7. The implantable medical device according claim 1, wherein the perfusion event is initiated by a premature ventricular contraction (PVC).

8. The implantable medical device according to claim 7, wherein the PVC is an intrinsic/spontaneous heart activity.

9. The implantable medical device according to claim 1, wherein the medical device is a heart stimulator comprising a heart stimulating unit and a heart event detection unit adapted to sense electrical heart events.

10. The implantable medical device according to claim 1, wherein the perfusion event is initiated by a premature ventricular contraction (PVC), wherein the medical device is a heart stimulator comprising a heart stimulating unit and a heart event detection unit adapted to sense electrical heart events, and wherein the PVC is provoked by altering the stimulation regimen applied by the heart stimulating unit.

11. The implantable medical device according to claim 9, wherein the perfusion event is provoked by creating an inter-ventricular dyssynchrony by applying predefined pacing therapy, by the heart stimulating unit.

12. The implantable medical device according to claim 9, wherein the perfusion event is provoked by applying hemodynamically poor pacing settings in order to induce a reduced perfusion, by the heart stimulating unit.

13. The implantable medical device according to claim 1, wherein the coronary perfusion measurement unit comprises an impedance measurement unit adapted to measure and determine parameters related to blood perfusion of heart tissue.

14. The implantable medical device according to claim 1, wherein the coronary perfusion measurement unit comprises an oxygen sensing unit adapted to measure and determine parameters related to blood perfusion of heart tissue.

15. The implantable medical device according to claim 14, wherein the oxygen sensing unit is adapted to determine S_vO₂ or pO₂.

16. The implantable medical device according to claim 1, wherein the coronary perfusion measurement unit comprises a photoplethysmography measurement unit adapted to measure and determine parameters related to blood perfusion of heart tissue.

17. The implantable medical device according to claim 1, wherein the device further comprises an ischemia analysis unit having a memory unit, the ischemia analysis unit adapted to receive the ischemia risk indicating index and to store it in the memory unit.

18. The implantable medical device according to claim 17, wherein the analysis unit is configured to determine changes of stored ischemia risk indicating indexes in order to identify positive or negative trends of those changes.

19. A method to determine an ischemia risk, comprising:

A) measuring and determining parameters related to coronary perfusion of heart tissue, the parameters include time periods and perfusion magnitudes;

B) determining a time period T related to a perfusion event of a coronary vessel and including a reperfusion time period, where the perfusion event is defined as a decrease of coronary perfusion followed by reperfusion,

C) generating a time period signal in dependence of the determined time period T;

D) processing the time period T and generating an ischemia risk indicating index I in dependence of the time period.

20. The method according to claim 19, wherein the time period T is determined as the time period that starts when the perfusion magnitude is at its minimum and ends when the perfusion magnitude is back to an initial perfusion level.

21. The method according to claim 19, wherein the ischemia risk indicating index I is directly dependent upon the time period T.

22. The method according to claim 19, comprising determining a perfusion magnitude measure Δ

p during a perfusion event, and generating a magnitude signal in dependence thereto and applying it to a coronary flow calculation unit, wherein the perfusion magnitude measure Δ

p is the magnitude difference between an initial perfusion level and the minimum perfusion level.

23. The method according to claim 22, comprising determining a normalized ischemia risk indicating index I_norm as I_norm=T/Δ

p.

24. The method according to claim 19, comprising detecting an initiating event resulting in a perfusion event, and starting a measurement window and activating a coronary perfusion measurement unit, upon detection of an initiating event, in order to determine the parameters related to the perfusion event.

25. The method according to claim 19, comprising provoking a premature ventricular contraction (PVC), initiating the perfusion event, by altering a stimulation regimen applied to the heart tissue.

26. The method according to claim 19, comprising creating an inter-ventricular dyssynchrony, provoking the perfusion event, by applying predefined pacing therapy to the heart tissue.

27. The method according to claim 19, comprising provoking the perfusion event by applying hemodynamically poor pacing settings in order to induce a reduced perfusion to the heart tissue.

28. The method according to claim 19, comprising measuring and determining parameters related to blood perfusion of heart tissue by performing impedance measurements.

29. The method according to claim 19, comprising measuring and determining parameters related to blood perfusion of heart tissue by performing oxygen measurements.

30. The method according to claim 19, comprising measuring and determining parameters related to blood perfusion of heart tissue by performing photoplethysmography measurements.

31. The method according to claim 19, comprising storing determined ischemia risk indicating index and determining changes of stored ischemia indicating indexes in order to identify positive or negative trends of those changes.